---
document_datetime: 2023-09-21 17:53:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/rilutek-epar-procedural-steps-taken-authorisation_en.pdf
document_name: rilutek-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4995436
conversion_datetime: 2025-12-23 01:05:52.939656
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Rh√¥ne-Poulenc Rorer, France, submitted on 3 July 1995, to the European Agency for the  Evaluation  of  Medicinal Products (EMEA), an application to  obtain  marketing authorisation  for the medicinal product Rilutek in accordance with the Centralised Procedure falling within the scope of Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr. D. Jefferys

Co-Rapporteur:

## 2. Steps taken for the assessment of the product

- The Co-Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 25 September 1995.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 27 September 1995.
- The  CPMP  during  their  meeting  on  17-19  October  1995,  considered  the  methodological problems concerning design, execution and statistical analysis of the clinical part and proposed an expert meeting on the 15 November 1995, with experts on neurology and statistics. A list of points to be answered by the company in advance of that meeting was also agreed and sent to the company on 20 October 1995.
- A summary of the  current  status of  methodological  issues  relating  to  efficacy  was  issued  on 27 November 1995.
- The CPMP final consolidated list of comments was sent to the company on 30 November 1995.
- The  company  submitted  the  responses  to  the  consolidated  CPMP  list  of  comments  on 22 December 1995.
- A Rapporteur/Co Rapporteur expert meeting was held on the 15 January 1996, to finalise the assessment report on the company's responses.
- The  Rapporteur's  'Responses'  assessment  report'  was  circulated  to  all  CPMP  Members  on 16 January 1996.
- The Co-Rapporteur's 'Responses' assessment report' was circulated to all CPMP Members on 19 January 1996.
- The CPMP in their meeting on 13-15 February 1996 discussed the recommendations presented by the Rapporteur and Co-Rapporteur. A hearing with the company took place on 13 February 1996 to address the final outstanding issues.

Amendments  were  made  accordingly  on  the  Summary  of  Product  Characteristics  and  User Package Leaflet texts.

- The CPMP on 14 February 1996 adopted a favourable opinion by scientific consensus.

Dr. P. Le Courtois